Strategic Partnerships Bluejay Diagnostics has engaged in distribution and strategic partnerships with government and manufacturing entities (Lovell Government Services, Argonaut Manufacturing Services) and collaboration with Sanyoseiko, signaling a proven path for channel expansion and federal healthcare access. This presents sales opportunities to expand into US federal channels and contract manufacturing partnerships for rapid scale.

Symphony Platform The company is actively developing the Symphony platform with lead IL-6 and broader near-patient diagnostics potential. This provides a compelling upsell and cross-sell path to existing customers for additional tests and to capture adjacent critical care segments as the platform matures.

Near-Patient Focus Bluejay concentrates on easy-to-use, point-of-care diagnostics and non-invasive tests such as Allereye Tear Total IgE and urine-based HIV testing. This aligns with urgent care, emergency medicine, and primary care markets seeking rapid results, offering recurring opportunity with clinics and hospital systems seeking faster decision support.

Early Stage Growth With a small team and sub-$1M revenue, there is high growth potential through strategic partnerships, federal distribution, and accelerated product launches. This suggests sales opportunities around pilot programs, joint marketing with channel partners, and pass-through sourcing arrangements.

Funding and Visibility A $33M funding base combined with active conference participation and press coverage around IL-6 testing and SAEM showcases increases credibility and buyer confidence. This can be leveraged in outreach and RFP responses to position Bluejay as a fast-moving, investor-backed innovator with tangible near-term test candidates.